Coris BioConcept

Coris BioConcept is a Belgium-based in vitro diagnostics company focused on rapid tests for human infectious diseases. The company develops, manufactures and markets CE-marked professional-use assays spanning respiratory, gastro-enteric and blood-borne pathogens, serology, and antimicrobial resistance testing. Its portfolio is particularly visible in rapid detection of carbapenemases and other resistance markers through the RESIST franchise, alongside products such as BL-RED, ReScape and selected PCR kits. Coris also offers CDMO services and operates from Gembloux with production, administrative and R&D capabilities on site. Founded in 1996, the company was acquired by Avacta in 2023 and subsequently sold to 3B BlackBio Dx in 2025, while continuing to operate under the Coris BioConcept name as part of the TRUPCR family.